Sputnik V Covid-19 vaccine may become generally available to public in late Oct-early Nov - RDIF
MOSCOW. Oct 12 (Interfax) - The coronavirus vaccine developed by Russia's Gamaleya Center could become generally available to the public at the end of October or at the beginning of November, Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said.
"We believe that the vaccine may be put into broad circulation in late October-early November," Dmitriev told the Rossiya 24 television channel on Monday.
More than 12,000 people have already been vaccinated as part of the post-registration trials, he said, adding that 600 of them have already been given the first and second injections and they are showing "a very good level of antibodies, and the clinical trials are going on successfully."
It is possible to produce 100 million doses of the Russian vaccine in Russia, and 500 million doses at local enterprises worldwide, he said.
As reported earlier, the United Arab Emirates (UAE) will conduct the Phase 3 clinical trials of the Russian vaccine. Representatives of 200 different ethnicities living in the UAE will take part in these trials, Dmitriev said.
More than 50 countries in CIS, Europe, Asia, Middle East and Latin America have applied for Sputnik V. RDIF has previously announced supply agreements with Mexico for 32 million doses, with Brazil for up to 50 million doses, with Egypt for 25 million doses, with India for 100 million doses, with Uzbekistan for up to 35 million doses, and with Nepal for 25 million doses.